Noticias de Eulerpool JCR Pharmaceuticals Co

JCR Pharmaceuticals Co Eulerpool-AFX

JCR Pharmaceuticals Co Noticias de Acciones

JCR Pharmaceuticals Co es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de JCR Pharmaceuticals Co.

• 3 de septiembre ·

  Yahoo
  JCR Pharmaceuticals Announces Completion of Clinical Trial Notification Process in Japan for Phase I Study of JR-441 for Mucopolysaccharidosis Type IIIA
• 18 de julio ·

  Yahoo
  JCR Pharmaceuticals Highlights Innovative Gene Therapy Research at the 7th International Forum of Lysosomal Disorders
• 2 de julio ·

  Yahoo
  MEDIPAL and JCR Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB
• 19 de marzo ·

  Yahoo
  JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with Alexion
• 29 de febrero ·

  Yahoo
  JCR Pharmaceuticals Celebrates Rare Disease Day 2024 and Highlights Its Commitment to the Rare Disease Community
• 14 de febrero ·

  Yahoo
  JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders
• 25 de enero ·

  Yahoo
  JCR Pharmaceuticals to Present at the 20th Annual WORLDSymposium™ 2024
• 21 de diciembre ·

  Yahoo
  JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration
• 21 de diciembre ·

  Yahoo
  JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® Technology
• 15 de diciembre ·

  Yahoo
  U.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)